Jump Financial LLC Takes $467,000 Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Jump Financial LLC bought a new stake in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) during the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 25,300 shares of the company’s stock, valued at approximately $467,000.

Several other hedge funds also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its stake in shares of Fulgent Genetics by 113.2% in the third quarter. JPMorgan Chase & Co. now owns 338,044 shares of the company’s stock worth $7,346,000 after acquiring an additional 179,477 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Fulgent Genetics by 803.2% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 125,957 shares of the company’s stock worth $2,326,000 after purchasing an additional 112,011 shares during the period. Inlight Wealth Management LLC purchased a new stake in Fulgent Genetics during the 4th quarter valued at approximately $685,000. Intech Investment Management LLC raised its position in shares of Fulgent Genetics by 248.3% during the fourth quarter. Intech Investment Management LLC now owns 43,539 shares of the company’s stock valued at $804,000 after buying an additional 31,037 shares during the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in shares of Fulgent Genetics in the fourth quarter worth $411,000. Institutional investors own 48.06% of the company’s stock.

Insider Transactions at Fulgent Genetics

In other Fulgent Genetics news, CFO Paul Kim purchased 100,000 shares of Fulgent Genetics stock in a transaction dated Wednesday, March 5th. The shares were purchased at an average cost of $15.96 per share, for a total transaction of $1,596,000.00. Following the completion of the acquisition, the chief financial officer now owns 348,282 shares in the company, valued at $5,558,580.72. This represents a 40.28 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 31.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on FLGT shares. Piper Sandler cut their price objective on Fulgent Genetics from $22.00 to $16.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. StockNews.com upgraded Fulgent Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, March 5th.

Fulgent Genetics Trading Up 0.7 %

FLGT opened at $19.04 on Friday. The stock has a 50-day moving average of $17.26 and a 200 day moving average of $18.16. Fulgent Genetics, Inc. has a 12 month low of $14.57 and a 12 month high of $25.11. The firm has a market cap of $587.69 million, a P/E ratio of -3.45 and a beta of 1.36.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.